Lexicon Pharmaceuticals | LXRX - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Abbott USD 6.8B 1.72B 2026-03
Acadia Pharmaceuticals USD 956.47M 105.02M 2026-06
Agios Pharmaceuticals USD 99.65M 13.95M 2026-06
Akebia Therapeutics USD 155.55M 7.1M 2026-06
Alnylam Pharmaceuticals USD 1.71B 2.46M 2026-06
AstraZeneca USD 4.89B 2.67B 2026-06
BioMarin Pharmaceutical USD 874M 1.35B 2026-06
Coherus Biosciences USD 82.92M 32.32M 2026-06
Eli Lilly USD 8.95B 3.67B 2026-06
Halozyme Therapeutics USD 163.14M 146.61M 2026-06
Illumina USD 1.09B 329M 2026-03
Insmed USD 544.76M 37.42M 2026-06
Ironwood Pharmaceuticals USD 220.47M 5.01M 2026-03
J&J USD 20.42B 1.27B 2026-06
Lexicon Pharmaceuticals USD 38.09M 3.76M 2026-03
MacroGenics USD 113.91M 47.39M 2026-06
MannKind USD 52.93M 95K 2026-06
Merck USD 6.85B 1.52B 2026-06
Moderna USD 1.72B 185M 2026-06
Novartis USD 7.62B 739M 2026-06
PTC Therapeutics USD 1.05B 215.9M 2026-06
Puma Biotechnology USD 53.52M 1.14M 2025-09
Sarepta Therapeutics USD 571.15M 106.7M 2026-06
Thermo Fisher Scientific USD 3.25B 6.6B 2026-03
Ultragenyx Pharmaceutical USD 125M 50M 2026-06
United Therapeutics USD 1.8B 523.5M 2026-06
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12